Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 4016-4025

  Sadun, Rebecca E ^a   Sachsman, Suzanne M ^a   Chen, Xiaoying ^a   Christenson, Kamilee W ^a   Morris, William Z ^a   Hu, Peisheng ^a   Epstein, Alan L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD83 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL MATURATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULINS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEOPLASMS;

EID: 34447132201     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0016     Document Type: Article

References (42)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
2. Malmberg KJ, Ljunggren HG. Escape from immune-and nonimmune-mediated tumor surveillance. Semin Cancer Biol 2006;16:16-31.
3. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006;24:175-208.
4. Zorn E, Hercend T. Anatural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol 1999;29:592-601.
5. Hayakawa Y, Smyth MJ. Innate immune recognition and suppression of tumors. Adv Cancer Res 2006;95:293-322.
6. Ling V, Chambers AF, Harris JF, Hill RP. Quantitative genetic analysis of tumor progression. Cancer Metastasis Rev 1985;4:173-92.
7. Owens DM, Wei S, Smart RC. A multihit, multistage model of chemical carcinogenesis. Carcinogenesis 1999;20:1837-44.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
9. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Clonal deletion of thymocytes as a tumor escape mechanism. Int J Cancer 1998;78:216-22.
10. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
11. Tomasi TB, Magner WJ, Khan AN. Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 2006;55:1159-84.
12. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103-24.
13. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003;21:807-39.
14. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001;24:392-407.
15. + regulatory T-cells in cancer. Semin Cancer Biol 2006;16:73-9.
16. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
17. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
18. So T, Lee SW, Croft M. Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity. Int J Hematol 2006;83:1-11.
19. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunology 2006;117:433-42.
20. Mocellin S, Wang E, Panelli M, Pilati P, Marincola FM. DNA array-based gene profiling in tumor immunology. Clin Cancer Res 2004;10:4597-606.
21. Hyatt G, Melamed R, Park R, et al. Gene expression microarrays: glimpses of the immunological genome. Nat Immunol 2006;7:686-91.
22. Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H, Yasui W. Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology 2005;69 Suppl 1:17-22.
23. Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003;63:8384-92.
24. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun 2006;343:684-91.
25. Abrams SI. Role of anti-CTLA-4 therapies in the treatment of cancer. Curr Opin Mol Ther 2004;6:71-7.
26. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
27. Hirano F, Kaneko K, Tamura H, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
28. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
29. Li J, Hu P, Khawli LA, Yun A, Epstein AL. chTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumors. Hybrid Hybridomics 2004;23:1-10.
30. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
31. Bernard A, Lamy, Alberti I. The two-signal model of T-cell activation after 30 years. Transplantation 2002;73:S31-5.
32. Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just amarker for maturation. Trends Immunol 2002;23:273-5.
33. + T cells: reversal by interleukin-12 stimulation. Blood 2003;101:3543-9.
34. Brunner C, Seiderer J, Schlamp A, et al. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000;165:6278-86.
35. Salceda S, Tang T, Kmet M, et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res 2005;306:128-41.
36. Tringler B, Zhuo S, Pilkington G, et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005;11:1842-8.
37. Sica GL, Choi IH, Zhu G, et al. B7-H4, amolecule of the B7 family, negatively regulates T cell immunity. Immunity 2003;18:849-61.
38. Nikolich-Zugich J. T cell aging: naive but not young. J Exp Med 2005;201:837-40.
39. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006;176:6434-42.
40. Muller AJ, Du Hadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
41. Liu A, Hu P, Khawli LA, Epstein AL. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005;11:8492-502.
42. Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35.